EUVIMEDDécouvrir EUVIMED
CrossrefCarte d’information

Evaluating the Efficacy of Dialectical and Cognitive Behavioral Therapies in Reducing Impulsive Behaviors

Mehran Rostamzadeh, Abbas Ali Husseini, William Mosier

Journal of Public Health and Primary Care · 2024

DOI: 10.4103/jphpc.jphpc_10_24 ↗
RésuméRéférences bibliographiques

Résumé

Abstract Background: Dialectical Behavior Therapy (DBT) and Cognitive Behavioral Therapy (CBT) are known to mitigate impulsivity in patients with borderline personality disorder (BPD). Aims and Objectives: This study aims to evaluate their impact on impulsivity in individuals without BPD. Materials and Methods: A non-randomized trial using a convenience sampling method, was conducted with 65 patients exhibiting impulsive behaviors who visited the Amir Kabir Medical Center in Arak between January 20 and March 20, 2023. After excluding those who did not meet the inclusion criteria, 48 participants remained. These participants were divided into three groups: two experimental groups receiving either DBT or CBT, and a control group with no intervention. Both experimental groups underwent 14 sessions of 45 minutes each. Pretest and posttest evaluations were conducted using the Barratt Impulsiveness Scale (BIS), and the data were analyzed using multivariate analysis of covariance. Results: The findings revealed a significant reduction in impulsive behaviors in both experimental groups compared to their pretest scores, with a statistically significant difference between the experimental and control groups. Conclusion: This study demonstrates that the techniques employed can serve as an effective behavioral treatment package for impulsive behaviors in non-BPD patients.

Des connaissances adaptées à votre travail.

D’un démarrage gratuit à la Research Suite complète, en passant par la recherche bibliographique personnelle.

Voir les tarifs →

Tous les textes intégraux sont-ils inclus ?

Non. Notices, résumés et textes intégraux sont des contenus distincts. La disponibilité dépend de la source, de l’accès ouvert et de vos licences. Une offre EUVIMED ne remplace pas des droits supplémentaires auprès des éditeurs.

Voir les tarifs →